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Human interleukin-4 (IL-4) is a small four-helix-bundle protein which is essential for organizing 
defense reactions against macroparasites, in particular helminths. Human IL-4 also appears to exert 
a pathophysiological role during various IgE-mediated allergic diseases. Seven different monoclonal 
antibodies neutralizing the activity of human IL-4 were studied in order to identify functionally 
important epitopes. A collection of 41 purified IL-4 variants was used to analyse how defined amino 
acid replacements affect binding affinity for each individual mAb. Specific amino acid positions 
could be assigned to four different epitopes. mAbs recognizing epitopes on helix A and/or C inter-
fered with IL-4 receptor binding and thus inhibited IL-4 function. However, other mAbs also inhibit-
ing IL-4 function recognized an epitope on helix D of IL-4 and did not inhibit IL-4 binding to the 
receptor protein. One mAb, recognizing N-terminal and C-terminal residues, partially competed for 
binding to the receptor. The results of these mAb epitope analyses confirm and extend previous data 
on the functional consequences of the amino acid replacements which showed that amino acid 
residues in helices A and C of IL-4 provide a binding site for the cloned IL-4 receptor and that a 
signalling site in helix D interacts with a further receptor protein. 
The formation of homo-oligomers or hetero-oligomers 
appears to be the crucial event during activation and trans-
membrane signaHing of cytokine receptors (Taga et al., 1989; 
Miyajima et al., 1992a, 1992b; Murakami et al., 1993). For 
certain receptor systems oligomerisation has been shown to 
be mediated by different receptor-binding sites exposed on 
the surface of the cytok.ine Iigand. For example, human 
growth hormone has two binding sites promoting the forma-
tion of a homodimeric growth-hormone-receptor complex by 
the sequential binding of two identical receptor subunits 
(Cunningham et al., 1991; Ultsch et al., 1991; De Vos et al., 
1992). Mouse interleukin-2 has three binding sites allowing 
the formation of a heterotrimeric receptor complex consisting 
of an a, ß and y-subunit (Waldmann, 1991 ; Taniguchi and 
Minami, 1993; Voss et al., 1993). Experiments in this study 
using neutralizing monoclonal antiborlies (mAbs) support the 
notion of the existence of two distinct functional sites in hu-
man interleukin-4 (IL-4 ). 
Human IL-4 is a small four-helix-bundle protein of 129 
amino acid residues that is essential for initiating defense 
reactions against parasites, in particular helminths (Paul, 
1991; Sher and Coffman, 1992). Human IL-4 also appears to 
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Abbreviations. IL-4, interleulcin-4; EC50, effector concentration 
resulting in half-maximal response; Rmax• maximal response ob-
tained at saturation Ievels; IC50, concentration resulting in half-maxi-
mal inhibition; IL-4Reu soluble IL-4 receptor; [K61Q]IL-4, interleu-
kin-4 in which Iysine at position 61 has been replaced by glutamine. 
exert a pathophysiological role during IgE-mediated allergic 
diseases (Finkelman et al., 1990; Romagnani, 1990). Re-
cently, a series of human IL-4 variants has been generated 
by in vitro mutagenesis (Kruse et al., 1991, 1992, 1993). 
Analysis of bioactivity and receptor binding revealed the oc-
currence of variants affected in IL-4 receptor binding (char-
acterized by an increased concentration affecting the half-
maximal response, EC50) and variants affected in receptor 
activation (characterized by a reduced maximal response ob-
tained at saturation Ievels, Rmax). The EC50 variants had been 
modified at amino acid positions in helices A and C, whereas 
the Rmax variants originated from arnino acid Substitutions in 
helix D. Thus, two functionally distinct sites appear to be 
present in human IL-4 which might promote the formation 
of the activated receptor oligomer. 
The binding site and the activation site in human IL-4 
should also be detected and defined by analysing the epitopes 
recognized by monoclonal antiborlies (mAbs) neutralizing 
the bioactivity. Such mAbs have been generated by several 
groups, since they represent important analytical tools for 
dissecting the function and biosynthesis of IL-4 (Ohara and 
Paul, 1985; Chretien et al., 1989; Solari et al., 1989). 
Furthermore, they are of potential therapeutic use as IL-4 
antagonists in vivo (Tepper et al., 1989, 1990; Urban et al., 
1991). 
The seven IL-4 neutralizing mAbs used in the present 
study were analysed by means of 41 purified IL-4 variants 
modified at defined single amino acid positions. Altered 
binding affinities between certain combinations of mAbs and 
IL-4 variants allowed the localization of at least four dif-
ferent binding regions. Epitopes on helices C and D of hu-
492 
man IL-4 have been identified recently by competition ex-
periments employing peptides representing particular seg-
ments (Ramanathan et al., 1993). Whereas these results pro-
vide preliminary evidence for a homodimeric IL-4 receptor, 
the present data strongly suggest a heterodimeric IL-4 recep-
tor system. · 
MATERIALS AND METHODS 
Materials 
Recombinant human IL-4 and mutant proteins were pro-
duced in Escherichia coli and purified as described pre-
viously (Weigel et al., 1989; Kruse et al., 1991, 1992, 1993). 
The IL-4 variants used in the present study have been desig-
nated as follows: H1Q; C3T; D4N; E9Q; E9K; C24T; 
E26Q; IQIQ; E41Q; E43Q; C46T; R47Q; R53Q; Y56D; 
H59Q; K61Q; C65T; R81E; R85Q; R88Q; R88D; W91R; 
C99T; Jillllil; E.l.Q1K; E114Q; K117Q; M120D; R121D; 
K123D; K123E; Y124D; Y124G; Y124F; Y124H; Y124K; 
Y124N; S125D; C127T; C127D; S128D. The number in 
the designation of the variants indicates the position altered 
by in vitro mutagenesis. The amino acid originally present in 
IL-4 is indicated by the first Ietter and the substituted amino 
acid by the seeond Ietter, both using the one-letter code. Mu-
tant proteins binding to the mAbs with affinities comparable 
tothat of IL-4 are underlined (Tables 2 and 3). 
The soluble IL-4 reeeptor (IL-4R..,.) was expressed in 
CHO cells and purified by affinity chromatography with IL-4 
coupled to CNBr-activated Sepharose 4 B (Pharmacia; Kruse 
et al., 1993). [3H]thymidine and Na125l were obtained from 
Amersham; N-hydroxysuecinimido Iong-ehain biotin and se-
condary antibody (goat anti-mouse lgG/alkaline phosphatase 
conjugate) were from Pierce. RPMI 1640, fetal calf serum 
and other eell culture reagents were supplied by Biochrom. 
Monoclonal antiborlies 
mAbs to human IL-4 were generated aecording to Galfre 
and MUstein (1981) and Peters and Baumgarten (1990). The 
mAbs 1G1, 4D9, 7D7, and 8F12 were generated in the labo-
ratory of Dr C. Heusser (Andersson et al., 1990), mAbs 
311106 and 3VD4 were established in the laboratories of 
Prof. W. Sebald and mAb 3B9 was selected by Dr B. Weston 
and coworkers. The immunization of Balb/c mice was per-
formed using recombinant human IL-4 and Freund's adju-
vant. Mouse spieen cells were fused with either NS/0 or PAI 
myeloma eells. After two weeks, the culture supernatants of 
fusion products were screened by ELISA using antigen-
coated microtiter plates or by RIA using sheep anti-mouse Ig 
coated plates and 1251-labeled IL-4. The concentration of 
mAbs purified by established procedures (Harlow and Lane, 
1988) was determined spectrophotometrically with an anti-
body eoneentration of 1 mg/ml yielding an absorbance of 
1.35 at 280 nm. 
T-cell proliferation assay 
Inhibition of T-cell proliferation (measured as detailed in 
Solari et al., 1989) was expressed as the molar concentration 
(IC50) of antibody that decreases by 50% the T-cell prolifera-
tion activity of recombinant human IL-4. The inhibitory con-
stant K; was determined using the equation K; = IC50/ 
(1 + [L]IEC50)with [L] representing the concentration of re-
combinant human IL-4 and EC50 the IL-4 eoncentration Iead-
ing to half-maximal proliferation of the T-cells in this system 
(0.2 nM). 
Protein modiflcations 
Biotinylation of reeombinant human IL-4 or IL-4~x was 
performed according to the manufacturers instructions at a 
fivefold molar exeess of N-hydroxysuccinimido Iong-ehain 
biotin over IL-4 or IL-4Rex· Recombinant human IL-4 was 
radioaetively labeled with 1251 using the IODO-GEN (1,3,4,6-
tetrachloro-3a,6a-diphenyl glycouril) method (Pierce) as de-
scribed previously (Cabrillat et al., 1987). The specific radio-
activity was determined in a solid phase competition assay 
as described (Kruse et al., 1993). The specific radioactivity 
of 1251-labeled IL-4 was 0.5-0.8 JlCilpmol IL-4. 
ELISA techniques 
Binding of mAbs to recombinant human IL-4 and mutant 
proteins was measured in a competiti ve ELISA (Harlow and 
Lane, 1988; Hornheck et al., 1991 ). Flexible assay plates 
(Falcon MicroTest 111) were coated with streptavidin and 
blocked. Biotinylated IL-4 (90 pg/ml) was bound to the 
streptavidin. After washing three times, mAbs at a constant 
concentration (100-500 ng/ml) were incubated with log2 di-
lutions of competitor (wild type IL-4 or mutant protein). Af-
ter three washes, a secondary antibody (anti-mouse IgG/alka-
line phosphatase conjugate) diluted 1:2000 was added. The 
plates were developed using p-nitrophenyl phosphate as sub-
strate and the absorbance at 405 nm was measured using a 
microplate reader (Dynateeh). From the inhibition curves, the 
IC50 value describing the competitor concentration allowing 
half-maximal binding of mAb to IL-4 on the solid phase was 
determined. The relative binding of mutant protein was de-
scribed as IC50(variant)IIC50(wild-type IL-4). 
mAb competition groups were established by measuring 
the competition between two mAbs ( one immobilised on a 
mierotiter plate, one in solution) for binding of biotinylated 
IL-4. 
Binding of mAbs to recombinant human IL-4 fixed to 
IL-4Rex was analysed by sandwich ELISA. The microtiter 
plates were coated with streptavidin and blockedas described 
for competitive ELISA. Biotinylated IL-4~x was added 
(100 pg/ml) for 1 h followed by incubation with recombinant 
human IL-4 (2 Jlg/ml) for 2 h. After three washes, log2 dilu-
tions of mAbs starting with 10 Jlg/ml were added. The 
following steps were performed as for competitive ELISA. 
Spot peptide synthesis and mAb binding assay 
Epitope mapping experiments by means of spot peptide 
synthesis were performed according to the manufaeturer's 
instructions (Cambridge Research Biochemieals; Frank and 
Döring, 1988; Blankemeyer-Menge et al., 1990). Overlap-
ping decapeptides covering the whole amino acid sequence 
of human IL-4 were synthesized on eellulose paper. The 
binding of mAb 3B9 to the peptides was analysed using a 
peroxidase-conjugated anti-mouse lgG (Dianova). The lumi-
nescence (Thorpe and Kricka, 1986) of the substrate (lumi-
nole) was detected by a Kodak X-OMAT film. 
RIA techniques 
To test the reactivity of mAbs 1G1, 4D9, 7D7 and 8F12 
with wild type IL-4 and mutant proteins, microtiter plates 
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Fig.l. Inhibition of IL-4 dependent T-cell proliferation by mAbs. 
Phytohemagglutinin-stimulated human T-cells were incubated with 
0.34 nM IL-4 plus the indicated concentration of mAbs 3IIID6 (0), 
3VD4 (e), 101 (0), 409 <•>. 707 (.6), 8F12 <•>. and 3B9 (\7). 
T-cell proliferation was deterrnined by [3H]thymidine incorporation. 
were coated with mAbs (20 J..Lg/ml). 1251-labeled IL-4 (1 nM) 
and competitor (wild-type IL-4 or mutant protein, 27 nM) 
were incubated on the plates for 1 h. The plates were washed 
three times and bound radioactivity was measured in a 
gamma counter (Packard Cobra 5005). The values given in 
Table 3 represent the inhibition of IL-4 binding by competi-
tor, expressed by the following equation: 
I= 100 (cpmmax- cpmx)/cpmmax• 
with I defming the inhibition (%), cpmmiu the maximal bound 
radioactivity in absence of competitor and cpm,. the bound 
radioactivity in the presence of competitor. 
Receptor-binding assay on T-cells 
Binding of 1251-labeled IL-4 to T-cells was performed as 
described previously (Kruse et al., 1992). Briefly, human T-
cells prestimulated with phytohemagglutinin were incubated 
with 0.8 nM 1251-labeled IL-4 in the presence of various con-
centrations of mAb (300 nM -1 pM). Separation of the cells 
from free IL-4 was achieved by centrifugation through sili-
con oil. The bound radioactivity was determined in a gamma 
counter (Beckmann). Ki values were calculated using the 
equation Kj = IC5o/(1 + [L]/Kd) with ICso describing the mAb 
concentration reducing the IL-4 binding to 50% of the maxi-
mal value, [L] the concentration of 1251-labeled IL-4 and Kd 
the dissociation constant of IL-4 for the IL-4 receptor 
(100 pM). 
RESULTS 
Properties of monoclonal antibodies 
All mAbs used in the present study were raised against 
recombinant human IL-4 produced in E. coli and belong to 
the subdass lgG1. These mAbs inhibited IL-4-dependent 
T-cell proliferation (Fig. 1), with mAb 3B9 and 8F12 being 
effective at doses stoichiometric to the applied IL-4 (Kj 60-
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Table 1. Properties of monoclonal antibodies. In Western blots, 
the signal strength was scored strong ( + + + ), fair ( + ), or no reac-
tion (-) for binding of mAb to recombinant human IL-4 blotted 
onto nitrocellulose membrane. The inhibitory constants K1 of the 
mAbs during a T-cell proliferation assay were determined from the 
IC50 values (Fig. 1) as detailed in the Materialsand Methods section. 
mAb Subtype Binding Competition K; 
to IL-4 in group 
Western blots 
nM 
3IIID6 IgG1 +++ III 3.9 
3V04 IgG1 I 13 
3B9 IgG1 +++ IV 0.06 
1G1 IgG1 II 29 
409 IgG1 + I 1.7 
707 IgG1 li 11 
8F12 IgG1 +++ I 0.1 
100 pM) whereas the other mAbs showed lower inhibitory 
activities with Kj values of 2-30 nM (see Table 1). 
. During spot-blot and Westem-blot analysis, mAbs 
3ßiD6, 3B9 and 8F12 reacted equally with native and dena-
tured IL-4 at amounts smaller than 10 ng. mAb 4D9 bound 
with lower affinity to the denatured IL-4 and the binding of 
mAbs 3VD4,1G1 and 7D7 could not be measured even with 
!arge amounts of the denatured protein. 
The mAbs could be divided into four groups with over-
lapping binding regions as determined by competition of two 
mAbs for IL-4 binding (data not shown), with group I corn-
prising mAbs 3VD4, 4D9 and 8F12, group II comprising 
mAbs 1G1 and 707. mAb 3IIID6 represents group III and 
3 B9 represents group IV. 
Altered binding of certain IL-4 variants 
to specific mAbs as measured by competitive ELISA 
Biotinylated IL-4 immobilized on streptavidin-coated 
wells of a microtiter plate was specifically recognized by the 
seven mAbs shown in Table 2. All mAbs, with the exception 
of 1G1 and 7D7, also bound to IL-4 directly coated onto 
the plates. The competition between immobilized IL-4 and 
soluble IL-4 or IL-4 variants for binding to the mAbs could 
be quantitatively determined by means of an alkaline-phos-
phatase-linked secondary antibody. Serial dilutions of the sol-
uble proteins yielded dose/inhibition curves as shown in 
Fig. 2, from which the concentration effecting 50% inhibition 
(IC50) could be derived. The examples employing mAb 7D7 
shown in Fig. 2 represent (a) variant [K61Q]IL-4 binding 
with an IC50 similar to IL-4 (relative IC50 approximately 1), 
(b) a variant [R88Q]IL-4 with very low affinity (relative 
IC50 > 30), (c) a variant [R53Q]IL-4 with low affinity (rela-
tive IC50 approximately 10) and (d) a variant [Y56D]IL-4 
with slightly reduced affinity (relative IC50 approximately 3). 
The relative IC5o values indicating a loss of binding affm-
ity could thus be classified into four categories as compiled 
in Table 2 showing one of two independent measurements 
performed with the indicated mAbs and IL-4 variants. A sub-
set of 12 of the IL-4 variants (see Materials and Methods 
section; underlined variants) bound during the competitive 
ELISA to all rnAbs with affinities which differed not measur-
ably from those of IL-4, and these variants are therefore not 
included in the table. A few variants, i.e. [H59Q], [C3T], 
[C24T], [C65T] and [C127T]IL-4, generally showed a 
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Fig. 2. Competition of IL-4 variants for binding of mAb 7D7 to 
immobilized IL-4 as measured during ELISA. The variants cho-
sen as typical examples demonstrate the competition at the indicated 
concentrations of U.-4 (0) and of variants K61Q (0), Y56D (.A), 
R53Q (.), and R88Q (T). 
slightly reduced reactivity to all mAbs (IC50 of 2-4 ). These 
variants most likely are structurally disturbed and therefore 
react to a lower extent ( data not shown). Three variants, i.e. 
[C46T], [C99T], [M120D]IL-4, showed a strongly reduced 
reactivity to all mAbs. The conformation of these variants 
appears tobe highly impaired (Kruse et al., 1991). 
The other IL-4 variants exhibit very specific and pro-
nounced binding deficiencies with certain mAbs only, as in-
dicated in Table 2. mAb 3IDD6 did not measurably react 
with variant [S128D]IL-4. Binding was reduced strongly 
with variants [D4N], [Y124D/G] and [C127D]IL-4, and to a 
minor extent with variants [H1Q]IL-4 and [K123D]IL-4. The 
three-dimensional structure of IL-4 (Fig. 4) demonstrates that 
the side chains affected in these variants are located at the 
C-terminus and N-terminus near to each other as expected if 
they were to form part of a common epitope interacting with 
mAb 3IIID6. 
A second pattem emerged with mAbs 3VD4, 4D9 and 
8F12, which all react very poorly with variant [E114Q]IL-4 
modified in helix D. mAbs 3VD4 and 4D9 werein addition 
very sensitive to the am.ino acid replacement in variant 
[R121 D]IL-4. The epitopes recognized by this group of 
mAbs comprise residues on helix D. 
A third group of mAbs, i.e. 101 and 7D7, showed low 
reactivity with variants [R88D]IL-4 and [W91R]IL-4. In ad-
dition, mAb 7D7 did not bind to variant [E9K]IL-4, and the 
reactivity with variants [R47Q], [R53Q] and [R81 E]IL-4 was 
reduced. These pattems probably indicate epitopes overlap-
ping at the lower end of helix C and extending with mAb 
707 to the upper N-terminal region of helixBand helix A. 
mAb 3B9, which in this study has the highest potency in 
inhibiting IL-4 bioactivity, revealed a loss of reactivity with 
only one of the available variants, i.e. [R81 E]IL-4 (with the 
exception of the extensively denatured variants). Apparently, 
the epitope of mAb 3 B9 extends over the N-terminal region 
of helix C. Binding analysis by means of spot peptides syn-
thesized on paper sheets (Frank and Döring, 1988; Blanken-
Table 2. Loss of binding aßinity of IL-4 variants to mAbs measured by means of competitive ELISA. The IL-4 variants with binding 
affinities similar to IL-4 were omitted from the table (see Materials and Methods section). The relative IC50 values of these variants were 
used to calculate the cut-off value (mean :±: SD). No entries in the table signify that the measured value was below the cut-off value. XXX, 
ICso values more than 30-fold higher than the IC50 of IL-4; XX, a 10-29-fold increased IC50 value; X, a 5 -9.9-fold increase in IC50 ; (X), 
IC50values increased less than 4.9-fold. 
IL-4 variant Monoclonal antibody 
3IIID6 3VD4 409 8F12 1G1 707 3B9 
H1Q (X) 
D4N XX 
E9Q 
E9K XXX 
R47Q X 
R53Q X 
Y56D X 
R81E XX XXX 
R85Q 
R88Q XXX 
R88D XXX XXX 
W91R XXX XXX 
E114Q XXX XXX XXX 
K117Q X (X) 
R121D XXX XXX (X) 
K123D (X) X 
K123E 
Y124D XX 
Y124G XX 
C127D XX (X) 
S128D XXX 
Mean 1.50 2.00 1.50 1.50 2.00 2.00 1.00 
so 1.00 2.00 0.50 1.00 1.50 1.50 0.50 
Cut-off value 2.5 4 2 2.5 3.5 3.5 1.5 
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Fig. 3. A synthetic nested set of IL-4 decapeptides binds specitically to mAb 3B9. The spot-peptide-syntbesis method (Blankemeyer-
Menge and Frank, 1990) was used to synthesize 120 nested decapeptides fixed in spots on a paper. The consecutive peptides, each shifted 
by one amino acid position, represent tbe whole IL-4 protein sequence. The paperwas incubated with mAb 3B9, and bound 3B9 was 
detected by a secondary antibody conjugate as shown at the right side of the figure. 
Table 3. Inhibition of IL-4 binding to mAbs by IL-4 variants. 
The symbols indicate tbe inhibition of binding of 1251-labeled IL-4 
to indicated mAbs as induced by various IL-4 variants. The cut-off 
value was set arbitrarily at the mean value minus three times the 
standard deviation measured for the binding of the other uncon-
spicuous variants (see Materialsand Methods section) to each mAb. 
No entries in the table indicate no change in inhibition of the variant 
compared to wild-type IL-4; XXX, XX and X indicate an inhibition 
lower than the mean value minus five, four or three times, respec-
tively, the standard deviation. 
IL-4 variant 
E9K 
R53Q 
Y560 
H59Q 
R88Q 
R880 
W91R 
E114Q 
K117Q 
R121D 
Mean 
SO 
Cut-off value 
Monoclonal antibody 
409 8F12 
XXX XX 
X 
XXX XX 
66 66 
13 13 
27 27 
1G1 
XX 
XX 
69 
11 
36 
707 
X 
X 
X 
X 
X 
66 
16 
18 
meyer-Menge et al., ·1990) revealed that partial sequences 
comprising residues His76, Lys77, Oln78 and Leu79 react 
specifically with mAb 389 (Fig. 3). These residues are also 
located on the N-terminal region of IL-4 helix C. 
Reactivity of IL-4 variants 
with mAb during radioligand binding 
The reactivity of the IL-4 variants with mAbs 1G1, 4D9, 
7D7 and 8F12 was analysed independently by means of a 
radioimmunoassay. This experimental setup should be less 
prone to possible artefacts originating from immobilizing 
IL-4 to the plastic surface. The results compiled in Table 3 
show that the binding of 1251-labeled IL-4 to for example 
mAb 101 is inhibited by 69 ± 11% (mean ± SD) in the pres-
ence of 26.7 nM IL-4 or most of the variants. Competition 
is significantly less, however, with variants [W91R]IL-4 or 
[R88D]IL-4. In the case of mAb 7D7, loss of binding oc-
curred in variants [E9K], [R53Q], [R88Q/D] and [W91R]IL-
4. The competition with mAb 4D9 revealed reduced affini-
ties to variants [E114Q], [K117Q] and [R121D]IL-4. Pro-
nounced binding deficiencies were found for mAb 8F12 in 
the case of variants [E114Q]IL-4 and [R121D]IL-4. These 
results largely confirm the data obtained by means of ELISA 
but some differences are evident. For example, [R121 D]IL-
4 was a poor Iigand for mAb 8F12 during RIA but not during 
ELISA. Defects in recognition of variant [R47Q]IL-4 by 
mAb 7D7 could not be detected during the RIA experiments. 
Location of epitope residues 
on the three-dimensional structure of IL-4 
The epitope residues identified during ELISA and RIA 
form patches on the surface of the IL-4 protein as depicted 
in Fig. 4. The largest clusters were identified with mAbs 7D7 
and 3IIID6. The surface areas on IL-4 postulated to fonn an 
epitope have dimensions of approximately 2 nmX2 nm for 
7D7 and 1.5X1.5 nm for 3IIID6 (Müller, T., unpublished re-
sults). It is interesting to note that the competition groups of 
the analysed mAb, as shown in Table 1, are compatible with 
the localization of the epitopes. Some overlap appears to ex-
ist in the case of Arg81 which might interact with mAbs 
from different groups (3B9 and 7D7). 
Competition between mAbs 
and soluble IL-4 receptor (IL-4R.,") for IL-4 binding 
The central issue of this study concerns the alignment of 
mAb epitopes and IL-4-receptor-binding sites. This problern 
could be addressed employing the extracellular binding do-
main of the known IL-4 receptor (IL-4Rex) isolated from the 
culture medium of transfected CHO cells. 
The recombinant extracellular domain of IL-4Rx immo-
bilized in the wells of microtiter plates binds IL-4 with Kd 
approximately 100 pM (Kruse et al., 1993), similar to the 
receptor on T cells or B cells. The recognition of receptor-
bound IL-4 by the various mAbs is demonstrated by the re-
sults of Saturation binding experiments as shown in Fig. 5. 
mAbs 3B9, 101 and 7D7 do not bind up to concentrations 
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Fig. 4. Location on a space-filling ·human IL-4 model of epitope residues for neutralizing mAbs as identified by the experiments 
described in Tables 2 and 3. A and E represent a model of the overall structure of IL-4 indicating the positions of the helices. The space 
filling models indicate the positions of epitope side chains for mAb 3lliD6 (B), 3VD4 and 409 (C), 8F12 (D), 1G1 (F), 707 (G) and 3B9 
(H). The upper row shows a view for helices D and A; elsewhere, a view of IL-4 helices C and B is depicted. The amino acid side chains 
which upon modification specifically weaken the binding of one mAb are shaded and designated by the one Ietter code. From Table 2, 
only amino acid positions yielding a relative IC,0 > 10 were considered. Amino acid positions drawn in brackets indicate that a change in 
binding could be detected only in one of the two assays, i.e. either ELISA or RIA. 
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Fig. 5. Binding of mAbs to the IL-4/IL-4 receptor complex. IL-4 
was attached to biotinylated IL-4Rc,. immobilized in the wells of a 
microtiter plate. The individual wells were incubated with the indi-
cated concentratioris of mAb 3IIID6 (0), 3VD4 (e), 3B9 (0), 101 
<•). 4D9 (~). 707 (A), 8F12 ('V), and a control IgG1 ('Y). Bound 
mAb was measured by a second alkaline-phosphatase-conjugated 
antibody. 
of 67 nM. The same background Ievels are observed with an 
isotype matched control mAb. This indicates that the bound 
receptor blocks the epitopes for these groups of antibodies. 
In contrast, saturation binding to a high Ievel is found with 
mAbs 3VD4, 4D9 and 8F12. mAb 3IIID6 also binds, albeit 
only at higher concentrations, so that saturation probably has 
not been achieved under the experimental conditions. The 
bindingwas specifi.c, since it depended completely on bound 
IL-4 during the assay (data not shown). This indicates that 
the epitopes of these groups of mAbs are spatially separated 
from the receptor-binding sites on IL-4, so that a simul-
taneous binding to IL-4 of both IL-4R..x and mAb is sterically 
possible. 
In a second set of experiments it could be demonstrated 
that mAbs 3B9, 1G1 and 7D7 inhibited binding of 1251-la-
beled IL-4 to the irnmobilized IL-4R.,,. whereas the presence 
even of a large molar excess of mAbs 3IIID6, 3VD4, 4D9 
and 8F12 showed only minor effects ( data not shown), thus 
confmning the results obtained in the sandwich ELISA. 
Influence of mAbs 3B9 and 8F12 
on tbe binding of IL-4 to T-cells 
During the present study, it has been shown that mAbs 
3B9 and 8F12 inhibit the IL-4-induced T-cell proliferation at 
doses nearly stoichiometric to the applied IL-4 concentration 
(K; 60 pM and 100 pM). The two mAbs exhibited a different 
effect, however, on binding of IL-4 to the isolated soluble 
IL-4 receptor. mAb 3B9 blocked binding of IL-4 to ll..-4R,,. 
completely, whereas mAb 8F12 could bind IL-4 simulta-
neously with IL-4R..x (Fig. 5). Thus, it was interesting to ana-
lyse how these m.Abs influence IL-4 binding to the functional 
receptor present on T-cells. As shown in Fig. 6, m.Ab 3 B9 
blocked binding of 1251-labeled IL-4 to the cellular receptor 
with an IC50 of 300 pM, corresponding to a K1 of 40 pM, 
whereas for 8F12 a more than 100-fold larger IC50 of 65 nM 
was determined (K1 = 10 nM). Since T-cell proliferation is 
inhibited at a much lower concentration, it is reasonable to 
conclude that mAb 8F12 is able to interact with IL-4 bound 
to the functional receptor on T-cells. 
DISCUSSION 
The neutralizing monoclonal antiborlies studied during 
the present experiments discriminate two functionally impor-
tant sites in human IL-4. One site is recognized by a group 
of m.Abs which compete with the known receptor protein for 
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Fig. 6. Inhibition of IL-4 binding to T-cells by mAbs 3B9 and 
8F12. T-cells were incubated with 12!11-labeled IL-4 plus the indi-
cated concentrations of mAbs 3B9 (0) or 8F12 (e). Bound 1251-
labeled IL-4 was detennined and calculated relative to maximal 
binding (in the absence of mAb). 
IL-4 binding. The second site is detected by those mAbs 
which are able to bind to IL-4 simultaneously with the recep-
tor protein. The IL-4 variants used in this study have been 
analysed before with respect to biological activity, physical 
receptor binding and structural integrity (Kruse et al., 1991, 
1992, 1993) and tumed out to be valuable tools in marking 
the epitopes of all seven mAbs employed in this study. Our 
mutational epitope scanning approach allowed the mapping 
of discontinuous or conformational epitopes which are diffi-
cult to analyse by other techniques. Moreover, low-affinity 
mAbs can be analysed. The epitope of one rnAb (3 B9) could 
be demarcated also by the spot-peptide-synthesis method. 
The epitope residues identified during the presented 
experiments cover major parts of the accessible surfaces of 
helices A-D. In the N-terminus and in helix A, informative 
amino acid exchanges occurred at the positions of His1, 
Asp4 and Glu9. No data could be obtained for the distal part 
of helix A. The major part of helix C was tagged by diagnos-
tic variants [R81E], [R85Q], [R88Q/D] and [W91R]IL-4. 
Nearly along the whole surface of helix D, residues were 
found that contributed to different epitopes, i.e. Glu114, 
Lys117, Arg121, Tyr124 and Ser128. Finally, one residue on 
helix B (Arg53) is involved in binding to mAb 7D7. X-ray 
analyses of antibody/antigen complexes have shown that in 
the case of Iysozyme (Amit et al., 1986; Sheriff et al., 1987) 
and influenza virus neuraminidase (Colman et al., 1987) con-
tact areas are approximately 2.5 nmX2 nm and comprise 
15-17 amino acid residues. Accordingly, even the IL-4 con-
tact residues identified for mAbs 707 and 3III06 most likely 
represent only part of the complete epitopes. The present re-
sults do not exactly define the borders between the individual 
epitopes. Competition experiments employing pairs of mAbs 
in all possible combinations revealed the existence of four 
groups: two mAbs each from a different group can bind 
simultaneously to IL-4. Since the competition binding was 
not analysed quantitatively, it might be possible that the epi-
topes of mAbs from different groups overlap partially, and 
that the first mAb attached to IL-4 lowers the binding affinity 
for the second mAb. The amino acid side chain of Arg81 
betonging to both the 3B9 and the 707 epitope might repre-
sent such an overlap. · 
mAbs 3B9 (group IV) and 7D7/1G1 (group II) competed 
efficiently with IL-4R.," for IL-4 binding. The identified IL-4 
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epitope residues for the group II and group iV mAbs there-
fore provide new informations on the binding site of IL-4 
for the known receptor protein. The epitope of mAb 7D7 
comprises side chains of Glu9 and Arg88. Arg88 also resides 
in the epitope of mAb 1 G1. Both side chains have been pre-
viously identified to interact with IL-4R," (Kruse et al., 
1993), because variants [E9Q/K]IL-4 and [R88Q/D]IL-4 
bind with reduced affinities to the receptor (EC50 variants). 
The finding that epitope residues of mAb 3B9 are localized 
at the proximal N-terminal region of helix C, strongly sug-
gests that the IL-4 binding site for IL-4R,x extends to this 
part of the protein. This conclusion is also in accordance with 
a recent study (Ramanathan et al., 1993) that human IL-4 
variants [K84I], [R88Qff] and [N89D]IL-4 are deficient in 
bioactivity and receptor binding. 
The most important conclusion drawn from the present 
results is that the IL-4 binding site for IL-4R.x does not ex-
tend to helix 0 and probably does not extend to the N-termi-
nal residues up to Asp4. This conclusion rests on the obser-
vation that the group I and III mAbs, whose epitopes are 
located in these areas, interfere only weakly (3TIID6) or mar-
ginally (3VD4, 409, 8F12) with IL-4Rex binding. mAb 8F12 
inhibits receptor binding of IL-4 only at more than 1 00-fold 
higher concentrations than that necessary to inhibit IL-4-de-
pendent T-cell proliferation. This small residual inhibitory 
activity for IL-4Rex binding may be due to a small overlap 
between the 8F12 epitope and the receptor-binding site, as 
the epitope borders are not defined clearly and the binding 
site for mAb 8F12 may extend onto helix A at undefined 
positions. The present findings contrast with a recent study 
on a rat mAb 25 D2 neutralizing human IL-4 bioactivity and 
receptor binding at an equally low concentration (0.33 nM) 
and interacting with an IL-4 peptide comprising C-terminal 
residues 104-129 (Ramanathan et al., 1993). These results 
are not necessarily at variance with the present results, since 
the epitope of rat mAb 25 02 could extend substantially into 
the binding site of IL-4Re,., most likely onto IL-4 helix A. It 
is interesting to note that in the human IL-6 system, a group 
of rnAbs was found which neutralized IL-6 bioactivity with-
out inhibiting IL-6 binding to U266 cells (Brakenhoff et al., 
1990, 1992). Possibly, these mAbs block the binding site on 
human IL-6 for gp130, but do not interfere with IL-6 binding 
to the low affinity receptor (IL-6Ra). 
What might be the explanation for the IL-4 neutralizing 
activity of group II and group III mAbs (3VD4, 409, 8F12/ 
3III06)? It is now generally agreed that the oligomerisation 
of receptor subunits represents the critical step leading to 
receptor activation. Applying an allosteric receptor-oligo-
merisation model (Schlessinger, 1988), these mAbs may 
block an allosteric signalling site on helix D of IL-4, thereby 
preventing a conformational change which would normally 
trigger receptor oligomerisation. Although such a mechanism 
cannot be formally excluded, severallines of recent evidence 
favour a sequential direct receptor oligomerisation via 
multiple binding sites on the IL-4 Iigand. IL-4 is structurally 
related to growth hormone and the IL-4 receptor belongs to 
the same family of receptors as the growth-hormone-binding 
protein. Similar to the human growth hormone, IL-4 might 
first interact with IL-4Rx via its binding site provided by 
residues on helices A and C. This complex creates an inter-
face including signalling residues on IL-4 helix D for the 
attachment of a second receptor subunit (Müller et al., 1994). 
An analysis of the charge distribution on human IL-4 and IL-
4Re,. (Demchuk, E., unpublished results) suggest the forma-
tion of a heterodimeric receptor, i.e. the second receptor sub-
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unit is not IL-4Rex· The recent finding of cross competition 
between human ~-4 and human ~-13 for binding to TF1 
cells (Zurawski et al., 1993) would be consistent with a se-
cond receptor subunit common to the IL-4 and IL-13 sys-
tems. However, it could be also visualized that an IL-13-
binding protein interacts with a hetero-dimeric or homodi-
meric IL-4 receptor complex, similar to the complex of cili-
ary neurotrophic factor/ciliary neurotrophic-factor-binding 
protein interacting with a heterodimeric receptor complex 
(Davis et al., 1993). 
Recent findings suggest that the y-chain of the interleu-
kin-2 receptor is a functional component of the IL-4 receptor 
(and also the interleukin-7 receptor) in murine as weil as in 
human cells (Russen et al., 1993; Kondo et al., 1993; No-
guchi et al., 1993). Thus, it is a reasonable assumption that 
the signalling site on helix D of human IL-4 interacts with 
this comrnon y-receptor subunit. lt can be easily visualised 
that mAbs directed against the signalling site block binding 
of the common y chain and thereby inhibit the biological 
activity of IL-4 but not IL-4Rex binding. 
The present results stress the importance of C-terminal 
residues and the surface of helix D for IL-4 bioactivity. The 
present study and a previous study reveal, however, that this 
region is not involved in binding to the known IL-4 receptor 
as often discussed (Le et al., 1991; Morrison and Leder, 
1992; Bamborough et al., 1993; Wlodawer et al., 1993; 
Ramanathan et al., 1993). It can be visualized that the two 
types of neutralizing anti-IL-4 mAbs (blocking or not block-
ing cell-surface receptor binding) behave differently in vivo. 
Possibly, organ distribution, clearance route and half life are 
different for a mAb binding to soluble IL-4 only and for a 
mAb also reacting with cell-bound IL-4. 
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